Key Developments: Peregrine Pharmaceuticals Inc (PPHM.O)

PPHM.O on Consolidated Issue listed on NASDAQ Capital Market

1.52USD
28 Jul 2014
Price Change (% chg)

$-0.03 (-1.94%)
Prev Close
$1.55
Open
$1.55
Day's High
$1.56
Day's Low
$1.47
Volume
1,819,273
Avg. Vol
1,241,408
52-wk High
$3.18
52-wk Low
$1.16

Search Stocks

Latest Key Developments (Source: Significant Developments)

Peregrine Pharmaceuticals Inc gives FY 2015 revenue guidance below analysts' estimates - Conference Call
Monday, 14 Jul 2014 04:30pm EDT 

Peregrine Pharmaceuticals Inc:Expects FY 2015 contract manufacturing revenue to be between $19 million and $23 million.FY 2015 revenue of $24 million - Thomson Reuters I/B/E/S.  Full Article

Peregrine Pharmaceuticals declares quarterly dividend on Series E convertible preferred stock
Tuesday, 10 Jun 2014 04:00pm EDT 

Peregrine Pharmaceuticals Inc:Declares a quarterly cash dividend payment on the company's 10.50 pct Series E Convertible Preferred Stock.Payable on July 1 to holders of record at the close of business on June 20.Quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share.  Full Article

Peregrine Pharmaceuticals Inc announces initiation of investigator-sponsored trial combining its Immunotherapy Bavituximab and Ipilimumab (Yervoy) in Advanced Melanoma
Wednesday, 23 Apr 2014 07:30am EDT 

Peregrine Pharmaceuticals Inc:Opening of investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's ipilimumab (Yervoy), for treatment of advanced melanoma.Bavituximab is upstream immune checkpoint inhibitor that targets phosphatidylserine (PS), a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells.Preclinical data in model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone.Bavituximab, Peregrine's lead immuno-oncology candidate, is being evaluated in second-line non-small cell lung cancer (NSCLC), as part of SUNRISE pivotal Phase III clinical trial.  Full Article

Peregrine Pharmaceuticals Inc presents data on bavituximab at AACR
Wednesday, 9 Apr 2014 11:00am EDT 

Peregrine Pharmaceuticals Inc:Presents data from studies validating immune-stimulatory mechanism of action of bavituximab.Demonstrating that combination of preclinical phosphatidylserine (PS)-targeting antibody with immune checkpoint inhibitors anti-CTLA-4 or anti-PD-1 antibodies yielded superior anti-tumor immune responses in animal models of melanoma.Says colon cancer compared to anti-CTLA-4 and PD-1 antibodies alone.Bavituximab is investigational immunotherapy being evaluated in second-line, non-small cell lung cancer (NSCLC) as part of SUNRISE pivotal Phase III clinical trial.Data from these combination studies are compelling as they provide further evidence that support immune-stimulatory effects of bavituximab in reducing prevalence of key immunosuppressive checkpoints in tumor environment.Reducing tumor-suppressive factors, reducing immune suppressor cells and providing increased tumor-specific immunity.These data also show that when combined with downstream immune checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1, PS targeting mediates improved protective tumor-specific immunity following tumor rechallenge.  Full Article

Peregrine Pharmaceuticals Inc updates progress in investigator-sponsored phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer
Friday, 14 Mar 2014 08:00am EDT 

Peregrine Pharmaceuticals Inc:Presentation of update to ongoing Investigator-Sponsored Trial (IST) of immunotherapy bavituximab in combination with the chemotherapy sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma (HCC) or liver cancer.Phase II portion of this trial is ongoing with 34 of 38 intended patients enrolled, 10 of which are on treatment with longest one on treatment for 18 months.This open-labeled trial is almost complete and while the results are preliminary, they are promising.Phase II portion of this trial is a single-center, single-arm, non-randomized, open-label trial with the primary endpoint of radiologic time to progression with imaging occurring at 6 week intervals.Secondary endpoints of trial include overall survival (OS), progression free survival (PFS), safety and response rates.Trial is scheduled to enroll 38 patients with advanced liver cancer.In order to leverage recent understandings surrounding the immune-stimulatory mechanism of action of bavituximab, several additional components have been installed into this portion of the trial.These include plasma and serum collection and tissue biopsies for evaluating changes in immune response following bavituximab treatment.Specifically, to assess whether combination therapy reactivates tumor immunity by changing the tumor microenvironment from immunosuppressive to immunoreactive, changing the tumor infiltrating cell composition or inducing T cell response to tumor antigens.  Full Article

Peregrine Pharmaceuticals Inc declares quarterly dividend on its series E convertible preferred stock
Tuesday, 11 Mar 2014 04:10pm EDT 

Peregrine Pharmaceuticals Inc:Declares a quarterly cash dividend on the company's 10.50 pct Series E Convertible Preferred Stock.Payable on Apr. 1 to holders of record at the close of business on Mar. 21.  Full Article

Peregrine Pharmaceuticals Inc reaffirms FY 2014 revenue outlook
Friday, 7 Mar 2014 08:00am EST 

Peregrine Pharmaceuticals Inc:Says it on track to be on the higher end of previously stated guidance for FY 2014 revenue of $18 and $22 mln.FY 2014 revenue of $22 mln - Thomson Reuters I/B/E/S.  Full Article

Peregrine Pharmaceuticals Inc announces closing of preferred stock offering
Wednesday, 19 Feb 2014 10:17am EST 

Peregrine Pharmaceuticals Inc:Closes previously announced underwritten public offering of 700,000 shares of its 10.50% Series E Convertible Preferred Stock at a public offering price of $25.00 per share.Says it has filed an application to list the shares of Series E Preferred Stock on the NASDAQ Capital Market under the symbol PPHMP.Holders of Series E Preferred Stock may convert their shares, in whole or in part, into shares of the company's common stock at a conversion price of $3.00 per share.Gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Peregrine, were about $17.5 million.MLV & Co. LLC book-runner.  Full Article

Peregrine Pharmaceuticals Inc announces public offering of series E preferred stock
Wednesday, 5 Feb 2014 04:01pm EST 

Peregrine Pharmaceuticals Inc:Says it intends to offer and sell shares of its newly-designated 10.50 pct Series E Convertible Preferred Stock in an underwritten public offering.Says in connection with the offering, the company intends to grant the underwriters a 30-day option to purchase up to an additional 15 pct of shares of the Series E Preferred Stock.Says the company intends to use the net proceeds from the offering for general corporate purposes.  Full Article

Peregrine Pharmaceuticals Inc receives FDA fast track designation for its immunotherapy bavituximab
Monday, 6 Jan 2014 07:30am EST 

Peregrine Pharmaceuticals Inc:Says has received fast track designation by the U.S. Food and Drug Administration (FDA) for its investigational immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer (NSCLC).Says the company initiated SUNRISE, a pivotal Phase III clinical trial comparing bavituximab plus the chemotherapy docetaxel against placebo plus docetaxel in this indication.Says SUNRISE is a Phase III, global, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, tolerability and efficacy of bavituximab plus docetaxel in patients with second-line non-small cell lung cancer.Says trial is evaluating bavituximab plus docetaxel versus docetaxel plus placebo in about 600 patients at more than 100 clinical sites worldwide.Says patients with Stage IIIb/IV non-squamous, NSCLC who have progressed after standard front-line treatment are eligible for enrollment.Says patients will be randomized into 1 of 2 treatment arms.  Full Article

Search Stocks